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EUPATI Belgium (EUPATI.be) is an informal gathering of local partners who are interested
in improving patient involvement in healthcare innovation and medicines research and
development. EUPATI.be brings together various stakeholders from different areas
related to healthcare including patients, academia and industry. In doing so, we create an
innovative collaborative approach where actors from different backgrounds work toward
improving patient involvement in medical research, and putting the patient at the center
of the Belgian healthcare system. Previously, we performed in-depth interviews with a
small group of stakeholders on patient involvement. Here, we elaborate on our previous
findings by using a nation-wide survey to inquire into Belgian stakeholders’ perception
on patient involvement. To this end, an electronic survey was available in French, Dutch
and English, and accessible for 11 months. Twelve questions were asked, including 11
multiple choice questions and 1 open question. The latter was thematically analyzed
according to the framework method. A total of 117 responses were registered and
descriptive statistics were performed. The majority of respondents could be categorized
into patient, academia and industry, whereas policy makers, payers, and healthcare
professionals were underrepresented. We identified several barriers that hamper patient
involvement, which were sometimes more reported by specific stakeholder groups. Next,
we found that various stakeholders still consider patient involvement as a passive role,
i.e., medical subject in a clinical trial. Respondents also reported that the role of the
various stakeholders needed more clarification; this was also confirmed by the level of
trust amongst the various stakeholders. Existing and the wish for more collaboration
with the various stakeholders was reported by almost all respondents. Based on this
survey, we can define the potential of involving patients in the medical research and
development in the Belgian landscape. Our results will help to understand and tackle the
various barriers that currently hamper patient involvement, whilst highlighting the need
for a collaborative landscape from the multi-stakeholder perspective.
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INTRODUCTION
Patients want access to affordable healthcare and healthcare
innovation. They are committed to invest and interact
with healthcare professionals and researchers, the relevant
authorities, and industry to speed up the medicines research
and development (R&D) process. In addition, patients wish
to provide their perspective and priorities to accelerate
the development of precision medicine, targeted therapies
and personalized care. Patient involvement is increasingly
recognized as an integral part of healthcare and a critical
component of safe and effective people-centered services.
Engaged patients are more able to make informed decisions
about their care options (1). Furthermore, resources may be
better used if they are aligned with patients’ priorities and
this is critical for the sustainability of healthcare systems
worldwide. Moreover, patient involvement also benefits
public support for biomedical research. A transparent,
timely and structured dialogue between all stakeholders in
the healthcare sector is the key ingredient to reach those
goals, which we confirmed while surveying the lifecycle of
medicines (2).
Patient-centered initiatives, such as the Innovative Medicines
Initiative (IMI) have greatly added to the awareness that patients
need to be at the center of a healthcare system. In order to
participate in this innovation process, the European Patients’
Academy on Therapeutic Innovation (EUPATI), a patient-led
public-private partnership was created in 2012 (1). EUPATI
aims to increase patient involvement by developing educational
toolboxes and trainings. Since communication needs to occur in
the patient’s mother tongue with patients has to happen in the
patient’s own language, EUPATI has facilitated the creation of
national platforms (ENPs). EUPATI.be, a platform for patient
education established as the Belgian chapter of EUPATI, has
been created in 2017. EUPATI.be’s main goal is to empower
patients through education. Led by patients, EUPATI.be provides
trainings based on the EUPATI toolboxes to render patients,
and other healthcare stakeholders, more educated about the role
they can play in the drug research and development process.
Furthermore, EUPATI.be aims to foster the national debate and
wants to be a key partner for government when developing
relevant health research legislation, policy and practice (2). By
broadly promoting patient involvement, patients become active
partners in medicine development.
While Belgium has already been experiencing a shift
from “reactive care” to P4 medicine emphasizing predictive,
preventive, personalized, and participatory care, the patient’s
role in this process is still not well-understood and needs
to be better defined (3). Better understanding of key drivers,
barriers and mechanism for effectively engaging the patient in
medical research is essential to improve the patient’s experience
and optimize healthcare systems (2). Our study provides an
important contribution in this direction by looking into the
perception of patient involvement in medical research from
the perspective of various stakeholders, including patients,
healthcare professionals, industry and policy makers. Bringing
this multi-stakeholder perspective on patient involvement is
crucial for developing mutual understanding and further
strengthening the patient’s roles in healthcare innovation.
METHODS
Survey Design
The survey was designed by the EUPATI.be Executive Committee
(ExCom), a balanced group of academics, patient and industry
representatives, to gain insight in the landscape of stakeholders
in patient involvement in Belgium, with a total of 12 questions
included (Supplementary File). Questions were included on the
following topics: patient role in medical research, collaboration,
understanding, trust, and barriers. Respondents were asked to
score statements for importance/frequency, with one as not
important at all/never; two as slightly important/rarely; three as
moderately important/sometimes; four as very important/often;
and five as extremely important/very often. An open-ended
question was included to elaborate on specific topics. The survey
was developed in three languages: Dutch, French, and English.
Survey questions were checked for clarity and comprehensibility
by various stakeholders attending a EUPATI.be Workshop
in October 2017; no adaptations were deemed necessary.
SurveyMonkey was used for the survey and to collect data.
Dissemination of the survey was done through the website of
EUPATI.be, and social media, including social media accounts
of individual EUPATI.be ExCom members, and their networks.
In addition, the survey was sent by email to affiliated research
departments of academic Executive Committee members. The
survey was accessible online from November 2017 until October
2018. Since this was a non-experimental, voluntary survey, where
no personal and sensitive data was collected, no ethical approval
was obtained.
Survey Analysis
Multiple Choice Questions
Responses were coded for analysis and descriptive statistics
were performed per question. All participants were included,
regardless of whether they completed the survey. In case
interpretations required the role of the respondent (e.g., patient
or industry), only the answers from respondents who reported
their roles were included. In case similar response rates were
observed across comparable categories, answers were pooled:
e.g., an encompassing category “Advising other stakeholders” was
created to pool the following answers “Advising pharmaceutical
companies,” “Advising academic researchers,” “Advising
regulatory agencies,” “Advising healthcare professionals,”
“Advising HTA agencies,” “Advising reimbursement agencies,”
and “Advising policy makers.”
Statistics and graphs were performed and created with
GraphPad Prism (version 7, San Diego, USA).
Open-Ended Question
The open-ended question asking for participants’ opinions on
how to improve patient involvement was analyzed thematically
using the framework method as described by Lacey and Luff (3).
Table 1 explains the implementation of the five iterative stages
of the framework method: (1) familiarization, (2) identifying a
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TABLE 1 | Stages of framework method.
1. Familiarization The answers to the open question 4 of the survey were
thoroughly read by the researchers involved in the
analysis (RJ, DD)
2. Identifying a
thematic
framework
RJ and DD independently assigned a label to all the
answers (“open coding”) before meeting to develop the
initial list of codes, i.e., the initial coding framework. The
initial framework was further discussed, refined and
agreed upon among the researchers involved in the
analysis (LL, EO)
3. Coding To assign the codes from the framework, the answers
were color-coded by one researcher (RJ), meaning that
each answer was given a color matching the code it
belonged to
4. Charting Excel was used to create a framework matrix for each
code from the final framework by one researcher (RJ)
5. Mapping and
interpretation
Using the Excel framework matrix created in stage 4, RJ
and DD independently searched for themes in the data
and convened afterwards to discuss their interpretations
(investigators’ triangulation). During these discussions,
RJ and DD reached consensus about stakeholders’
proposed solutions on how to improve patient
involvement and subsequently derived the themes and
illustrative quotes in the results sections More Education
and Information, More Favorable Regulatory and Ethics
Environment, More Awareness, Communication and
Trust, and A Systematic and Structured Approach. This
stage was guided by the research question, the barriers
for patient involvement highlighted by participants in
question 3 and a careful analysis of what was in the data.
Interpretations were made by reviewing the matrix and
making associations within codes and interviewees, as
well as between codes and interviewees. Whenever the
data was rich enough, the interpretations generated in
this stage went beyond the description of a particular
interviewee to the explanation of potential reasons or
beliefs of multiple interviewees
thematic framework, (3) coding, (4) charting, and (5) mapping
and interpretation. The triangulation of the involved researchers
is shown in Table 1 as well.
RESULTS
Participants’ Demographics
A total of 117 individual respondents participated, but not
all respondents completed the full survey. The demographics
of the respondents is presented in Figure 1. The majority of
respondents were located in Flanders (52.1%) and in Brussels
(35.2%). Wallonia and other regions were less represented; 9.9
and 2.8%, respectively (Figure 1A). We observed comparable
contributions from the patient community (30.6%; including
individual patients and (non)-patient representatives), academia
(23.6%), and the industry (22.2%) (Figure 1B). Less than
one out of five was represented by “Other.” Policy makers,
payers and healthcare professionals were the least represented
among respondents (4.2 and 2.8%, respectively). The therapeutic
areas were variably represented (Figure 1C); the majority of
respondents were related to areas not predefined in the survey
(22.7%) and oncology was the second-most represented (18.5%).
Representation from the fields of rheumatology, vaccines,
cardiovascular, and infectious diseases were also considerably
present (9.2–10.1%).More than a third was familiar with EUPATI
(38.8%), whereas a comparable portion (36.4%) of respondents
were unfamiliar with EUPATI or other initiatives and projects
on patient involvement and education in healthcare innovation.
Still, more than 1 out of 10 either knew about or were involved in
other initiatives (9.3 and 7.0%, respectively; Figure 1D).
Patient Involvement: Settings and
Importance
Various settings were presented in which patients could be
involved and participants were asked to indicate how important
patient involvement would be in each setting. The results are
illustrated in Figure 2A. Although no setting scored below 3,
a subtle ranking could be observed in the average importance
rated by respondents. To highlight these subtle differences, a
gradient of passive to active participation is shown on the right in
Figure 2A. Overall, participation in medical research as subjects
was found as the most important setting for patient involvement,
whereas application for funding was considered least important.
A subanalysis per stakeholder was made to characterize the
importance in-depth and is presented in Table 2. Here, we found
that the industrial stakeholders perceive participation as medical
subjects as the most important form of patient involvement.
The subanalysis showed no remarkable deviations in average
scores although policy makers and payer representatives found
“presenting at conferences and workshops” less important than
other stakeholders. Furthermore, the same group also found
participation in application for funding together with academia
and industry less important, with an average score of 2.3, whereas
other scores ranged from 3.3 to 4.1 amongst the rest. Remarkably,
active participation in patient organizations was highly rated by
all stakeholder communities.
Collaboration With Actors in Healthcare
Innovation
Figure 2B illustrates the collaboration with the various
stakeholders for healthcare innovation. Respondents
could also indicate whether more collaboration was
preferred. With almost half of the votes, payers were not
involved in healthcare innovation, although 17.9% of the
respondents reported a wish to collaborate more with
this stakeholder group. Not surprisingly, academia and
healthcare professionals represented the major collaborators,
whereas the latter were also seen as potential added
value for future collaborations (32.8% to collaborate
more). Patient organizations and individual patients each
represented more than a third with whom collaborations are
ongoing, and up to 23.5% wanted more collaborations with
these actors.
Understanding Actor’s Roles in Medical
Research and Development
Respondents were also asked if they knew the role of each
actor in medical research and development (Figure 2C).
Frontiers in Medicine | www.frontiersin.org 3 February 2020 | Volume 7 | Article 36
Grine et al. Patient Involvement in Belgium
FIGURE 1 | Characteristics of survey respondents. Respondents were inquired into a selection of basic demographics such as (A) region; (B) role; (C) disease field;
and (D) familiarity with EUPATI (-like) initiatives.
Very similar numbers were found for each actor and for
each category of response, except for the payers’ role which
was perceived as least understood (14.7%). The roles were
however not entirely clear, since approximately half of
respondents wished to better understand all roles, with
percentages ranging from 44.1 to 59.4%, indicative for a gap in
healthcare innovation.
Trust in the Different Stakeholders
Next, we sought to understand the trust amongst stakeholders,
which is illustrated in Figure 2D. Surprisingly, trust in academia
surpassed the trust instilled in patient organizations or
individual patients (96.67 vs. 76.57, and 75.71%, respectively).
Healthcare professionals were trusted by a comparable number
of respondents (77.14%). Yet, for these actors, about 1 out of 4
respondents indicated to not trust them. Even more surprising
was the low trust found in the groups policy makers, regulators
and payers, reaching only a maximum of 30.42%. A minority
reported to have no trust in these actors; the remaining found it
hard to say. The industry was trusted by 50% of the respondents;
whilst 37.50% indicated to find it hard to say whether they trusted
the industry.
Patient Involvement: Barriers and Solutions
Among 73 participants who answered the open-ended question,
16 were academics, 4 healthcare professionals, 20 patient
organizations, 31 industry, and 2 policy-makers/regulators.
The barriers and solutions for patient involvement indicated
by participants related to (i) education and information,
(ii) regulatory and ethics environment, (iii) awareness,
communication and trust, and (iv) systematic and structured
approach. None of the presented barriers in the survey
(Figure 2E) received an average score below 3.0, indicating
that the average frequency with which participants encountered
these barriers ranged from sometimes (3) to very often (5).
The three barriers receiving the highest average scores were:
“patients do not have access to relevant information” (4.5), “lack
of financial resources and personnel” (3.9) and “patients need
to be seen as equal partners” (3.8). Conversely, “the industry
code is not supportive” (3.0), “patients are reluctant or afraid”
(3.0) and “healthcare providers are not supportive” (3.3) were the
three barriers receiving the lowest average scores. Two barriers
were identified as often hampering including patients, including
“the lack of acknowledging the patient as a partner” and “the
lack of knowledge and skills amongst patients.” Practical issues
such as regulatory, legal and political constraints and lack of
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FIGURE 2 | “Perception on the various aspects of patient involvement.” Respondents were asked to reply to statements with a degree of agreement on aspects
including (A) the importance of the patient in medical research, (B) collaboration, (C) the role of each stakeholder, (D) trust, and finally (E) barriers.
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TABLE 2 | Patient involvement rated per stakeholder.
Patient community Hcp and academia Industry community Policy and payers Other
Applying for funding 4.0 3.3 3.4 2.3 4.1
Presenting at conferences/workshops 4.1 3.7 4.0 2.8 4.5
Participating as patient researcher 4.4 3.8 3.9 3.5 4.2
Advising other stakeholders 4.6 3.9 4.4 3.6 4.5
Discussing research priorities 4.4 3.8 4.3 3.8 4.7
Active role in patient organizations 4.9 4.4 4.5 4.8 4.6
Participating in medical research (clinical trials) 4.5 4.5 4.9 4.5 4.7
resources such as personnel and finances were also indicated
as “often.” All other barriers were still present as none scored
’never frequented’. When analyzing the barriers in detail per
stakeholder (Table 3), we observed that financial resources were
reported as a major barrier by most stakeholders: the highest
and lowest frequency in the “other stakeholders” and “policy and
payer” categories, respectively. Similarly, lack of resources such
as finances and personnel was also seen as a significant barrier;
where the lowest score was again in the policy and payer category.
The same stakeholder group also scored least for the barrier of
“fear amongst patients to participate in medical research due
to risks.” This stakeholder, however, rated a fragmented patient
community as a major barrier, which was also rated highly
amongst the other stakeholders. Interestingly, the industrial
community also indicated this as their top barrier. Furthermore,
the latter also viewed the lack of involvement between patients
and healthcare professionals due to lack of knowledge and skills
on the patients’ side as a barrier. The solutions described by
participants are detailed below and in Table 4.
More Education and Information
Participants from different stakeholder groups (academics,
patient organizations, patients, industry, policy makers)
described that in order to be able to participate in discussions on
topics about drug research and development (e.g., clinical trial
design), patients should be better informed and educated about
their disease and how drug development works:
“First we have to make sure patients can easily access the
information necessary to be able to speak about a certain topic.
Then we could have them sit at the table as a full-fledged partner
in the debate.” (patient organization representative)
Some participants mentioned that not only patients, but also
other healthcare stakeholders, such as patient organizations, the
general public, and journalists need to be better informed about
the drug development process. Participants highlighted thatmore
information is needed about how clinical trials work and that
this information should be adapted to patient needs and be clear,
simple, interactive but also honest, up-to-date and correct. Access
to such information would also increase patients’ confidence
to participate in discussions and their trust in pharmaceutical
companies and drug development according to two participants
(see below). Specific approaches for informing and educating
patients brought forward were via: (i) media (“digitization”),
e.g., infographics or videos, (ii) interactive conversations in
the medical doctors’ office to receive patients’ feedback, (iii)
workshops in which patients are informed and educated by
researchers and physicians on their disease, and (iv) brochures
developed by the government. Several patient organization
representatives mentioned that specific education should be
available to train patients as “patient experts.” One respondent
further explained that such training should include a quality label,
and another respondent proposed that such experts should be
present in all pathologies. Some respondents suggested channels
to disseminate information, including (i) schools (to educate the
general public on drug development), (ii) patient organizations,
and (iii) healthcare professionals, including general practitioners
and specialists.
More Favorable Regulatory and Ethics Environment
Some participants described how patient involvement could be
achieved by providing a bigger regulatory and ethical incentive
toward pharmaceutical companies and healthcare providers.
At the regulatory level, some participants argued that the
government1 and politicians need to have an unambiguous
opinion toward stakeholders on the desirability of patient
involvement and push patient involvement toward healthcare
providers and industry. Some continued that patient involvement
and education should be made mandatory:
“A bigger policy push forcing industry and healthcare providers to
include patients” (industry/ professional association member)
In this context, one industry member specifically mentioned
that more interaction between politics and industry is needed.
Another industry member was convinced that the involvement
of patients by industry is currently ethically prohibited because
of “bias risk,” and a third industry member pointed out that
clear guidelines on how industry can approach patients should
be made available.
More Awareness, Communication, and Trust
Patients have a pivotal role to play in medical R&D and
clarifying this role and associated responsibilities was expressed
1Both the government on the national level, the “Federal Agency for Medicines
and Health Products” (FAMHP), and the government on the European level
were mentioned.
Frontiers in Medicine | www.frontiersin.org 6 February 2020 | Volume 7 | Article 36
Grine et al. Patient Involvement in Belgium
TABLE 3 | Barriers encountered per stakeholder.
Patient community Hcp and academia Industry community Policy and payers Other
Patients do not have access to relevant information 3.4 3.1 3.8 2.5 4.3
Patients need to be seen as equal partners 4.5 3.4 3.6 4.0 4.3
Patients are not prepared, need more knowledge and skills 4.0 3.4 3.5 3.5 4.3
Patients are afraid or reluctant 3.3 3.0 3.2 2.5 3.5
Fragmentation of the patient community 3.6 3.4 3.6 3.9 4.0
Individual patients are not representative 3.5 2.9 3.1 2.5 3.3
There are not enough opportunities for patients to engage 4.0 2.3 3.9 3.8 3.8
Healthcare providers are not supportive 3.2 4.2 3.3 2.8 3.8
The industry code is not supportive 2.8 3.0 3.7 2.5 3.4
Regulatory, legal and political constraints 3.8 3.5 4.0 2.0 4.2
Lack of resources (personnel and financial) 4.6 4.3 3.8 2.8 4.2
TABLE 4 | Barriers and solutions proposed by the respondents.
Barrier: a lack of Solution: need for more
Education and information • Patients are not prepared and need more knowledge
and skills
• Patients do not have access to relevant information
• About drug development & disease process
• To increase patients’ confidence & trust regarding drug
development
• Using interactive approaches
• Via patient organizations, schools
& healthcare professionals
Favorable regulatory and ethics environment • Regulatory, legal, and political constraints
• Industry code is not supportive
• There are not enough opportunities for patients
to engage
• To create a bigger incentive
• Toward pharmaceutical companies and healthcare
professionals
• Via a clear position statement from the government
and clear guidelines on how to approach patients
Awareness, communication, and trust • Patients are reluctant or afraid
• Patients need to be seen as equal partners
• Healthcare professionals are not supportive
• Amongst healthcare stakeholders
• Align stakeholders on the role of patients in R&D
• Conferences, meetings and awareness campaigns
Systematic and structured approach • Lack of financial resources and personnel
• Fragmentation of the patient community
• Individual patients are not representative
• Involve patients early and at all phases of drug R&D
• Ensure a representative voice of patients when
participating in discussions
• Recognize and compensate patients for their
contributions
• Facilitate information sharing & collaboration
between stakeholders
as an opportunity to align different partners to obtain more
impactful patient involvement. In order to respect patients as
equal partners, their role must be well-understood by all players.
To this end, we identified the need to improve the general
awareness about patient involvement. This could be obtained
through different means, including events such as awareness
campaigns, patient involvement conferences, EUPATI-events
and/or patient organization meetings. The latter would allow
early and timely detection of patient’s needs and priorities and
enable early patient involvement.
“We need to inform the general public on what is clinical
research. Still too many patients do not believe in research or trust
companies” (academic rep)
Furthermore, patients want to be kept informed about the
latest research updates and learn about patient involvement
opportunities in different areas and with different stakeholders.
A few examples included regular meetings with pharma.be, the
federal agency for medicines and health products (FAMHP),
researchers, and hospitals. In addition, by providing more
information, for instance on clinical studies, may directly address
the patients’ fears related to medical R&D, hereby improving
dialogue with and trust toward different stakeholders.
A Systematic and Structured Approach
Involving patients early during medical R&D was acknowledged
as a crucial factor. This also included the involvement of
patients at every level of the hospital-management pyramid.
Allowing patients to co-design the endpoints of a clinical
study and study protocols overall was described as one of
the key activities where patients can add a lot of value.
Moreover, communication between patient and physician was
also reported: 3 different stakeholders (patient, doctor, and
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academic) specifically addressed the need for more time for
dialogue during consultations.
“Patient empowerment should be enhanced through a carefully
designed healthcare team that regularly engages with the patient to
identify needs”
In addition to a better understanding of the roles, representation
of stakeholders was identified as a quality criterion to a multi-
stakeholder approach. Remarkably, one respondent thought that
a patient is unable to represent a broader patient community.
This was reinforced by the notion that the role of the patient
is not sufficiently valued: fair compensation and recognition for
patients and patient representatives was identified as a valuable
opportunity. Some solutions included considering subsidized
patient advocate roles and compensating patient organizations.
This in itself would tackle a financial issue since patient
organizations often struggle with funding. It was also postulated
that companies that truly invest in patient involvement could
be rewarded, hereby stimulating the industry. The latter two
arguments would simultaneously address the bias risk mentioned
previously in section c.
According to the respondents, the availability and accessibility
of accurate information is still challenging. Therefore, easy
access to information in an open infrastructure, accessible to
different types of stakeholders may facilitate interactions and
collaboration. Guidance and tools to support a broad range of
patient representatives are needed to enable them, and may also
be beneficial for other stakeholders.
DISCUSSION
This study sheds light on the Belgian landscape for patient
involvement where multiple stakeholders in medical innovation
report on their experiences. EUPATI.be’s mission to facilitate
development of patient expertise is highly dependent on its
position in this landscape: this is reflected by the main finding
that more than a third of the 117 respondents is familiar
with EUPATI.be. Understanding how the different stakeholders
perceive patient involvement is key to develop a platform to
facilitate interaction between patients and stakeholders. Our data
shows that patient involvement is still seen as the participation
of patients as medical subjects in research, rather than an active
and equal partner in decisionmaking at the research, medical and
regulatory level. This in itself needs to be addressed by creating an
ecosystem in which patient expertise is acknowledged and valued
by different stakeholders. However, this acknowledgement will
only occur when patient input is provided professionally in a
culture where patient (experts) are perceived as equal partners.
Regulatory agencies, such as the European Medicines Agency
(EMA), have led by example, involving patient organizations
and their disease-specific expertise to revise the design of
clinical trials, e.g., the Medicines Adaptive Pathways to Patients
(MAPPS) (4).
EUPATI’s guidelines on patient involvement distinguishes 4
domains, including pharmaceutical industry-ledmedicines R&D,
ethics committees, regulatory processes, and health technology
assessment (HTA). Although patient involvement in R&D may
seem obvious, there remains a need for platforms: EUPATI and
IMI both focus on facilitating this interaction with and for
the industry. In addition, different initiatives exist such as the
Patient-Centered Outcomes Research Institute (PCORI), FDA’s
Patient-Focused Drug Development (PFDD) initiative, Clinical
Trials Transformation Initiative (CTTI), and the Patient Focused
Medicine Development (PFMD) coalition. The involvement of
patients during HTA seems less obvious, although this is where
another major impact on patients occurs - between scientific
evidence and decision making. The Belgian Health Technology
Assessment “KCE” has published their position on patient
involvement in November 2019, stating the needs for structural
and organizational requirements and revisiting their internal
culture on patient involvement, with a main focus on how patient
involvement is to be regarded as complementary to scientific
evidence (5). But also funding agencies are increasingly aware
of the need for dialogue. In May 2019, the King Baudouin
Foundation organized a symposium “Mind the Gap” on how
different stakeholders can collaborate to set research priorities
(6), exemplified by the UK-based James Lind Alliance (http://
www.jla.nihr.ac.uk/). Indeed, our findings confirm that, despite
many topdown and bottom-up efforts (7, 8), true patient
involvement remains challenging.
Our survey generated an overview of the foremost barriers
hampering patient involvement experienced by the different
stakeholders, and simultaneously allowed respondents to suggest
solutions. These suggested “bottom-up” approaches may form
the most immediate solutions to tackle the challenges. The
four barriers “lack of education and information,” “lack of
favorable regulatory and ethics environment,” “lack of awareness,
communication, and trust,” and “lack of a systematic and
structured approach” are considered most urgent to be tackled.
The high rate of clinical trial failures represents an ideal
opportunity to explore these barriers and solutions during the
different steps of clinical trials (9). However, patient involvement
can also occur at a more practical level as evidenced by a case
study on pharmaceutical packaging (10).
Furthermore, our study shows that, for the Belgian ecosystem,
there is a clear willingness to increase patient involvement
at various levels, despite existing barriers. EUPATI.be aims to
remove the existing obstacles by filling the gaps defined in
the ecosystem of patient involvement by focusing on patient
education, awareness and strategic collaborations, forming the
basis to expand the roadmap of EUPATI.be.
Patient Education
Effective patient involvement is fundamental to boost the safety
and efficacy of novel therapies, whilst ensuring that novel
treatments truly cater to the patients’ needs. To increase patient
involvement in medical R&D process, patients need to be armed
with a deep understanding of the healthcare ecosystem during the
various steps in the development process, including terminology.
Educating patients to become bespoke experts and advocates is
therefore key (11). Therefore, EUPATI.be’s mission is to provide
this education: complementary to the EUEUPATI course of 270 h
online training (based on the EUPATI toolboxes and face-to-face
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meetings), we also develop educational workshops for the broad
public. These workshops are rather topic-specific than disease-
specific, and its modules are developed to relate to general
knowledge, such as clinical trials, biological drugs and vaccine
confidence. The workshops can also be tailor-made for the
fragmented and multi-faceted Belgian healthcare system. In fact,
due to Belgium’s federal and regional infrastructure, a myriad of
organizations and institutions are active in the healthcare system,
leading to a multitude of healthcare stakeholders involved
to provide health services, in particular diagnosis, treatment,
and cure, but also, and increasingly important, prevention
to the patient. Although other actors, such as agencies for
pricing and reimbursement, HTA or insurance companies, do
not directly provide care to the patient, they also play a
crucial role in the accessibility of healthcare services. To deal
with this complexity and improve understanding amongst the
stakeholders, EUPATI.be’s workshops explain the roles, tasks,
the mission and the responsibilities of the various Belgian
healthcare actors. The workshops are driven by demand and can
be developed upon request. The ultimate aim of these interactive
workshops is to create better awareness of how and where in the
process patients can provide input and hence be the driving force
in the clinical development of new therapies.
Creating Awareness
A White Paper will be published on the current status and
opportunities of patient involvement in Belgium based on the
2018 survey. This White Paper will be widely distributed to
patient organizations, policy makers, academics, industry and
clinicians. Furthermore, EUPATI.be will continue to carry out its
mission on public events, including its own annual conference,
whilst pro-actively contacting patient organizations to set up
long-term collaborations.
Strategic Collaborations
Collaboration is essential for innovation in healthcare and in
order to make collaborations successful and sustainable, all
partners should be considered as equals. Hitherto, trust is
a key concept, and all actors need to align on a common
mission and vision. Since strong collaborations often build upon
bridging knowledge gaps and crossing disciplines, EUPATI.be
will leverage its strength of being composed by members
from patient organizations, academia, and industry to enhance
awareness about patients’ needs and preferences, and facilitate
communication and trust between the various stakeholders.
Hitherto, all stakeholders can plea with the governing authorities
and regulatory bodies for an unambiguous position on how
to increase patient involvement. EUPATI has guidelines that
can be employed for this stance (e.g., the EUPATI Guidelines)
(4, 12, 13). By collaborating strategically, EUPATI.be can
establish a platform where patients and decision-makers
can interact in a more structured and ethical way. This
will require major efforts to establish trust between all
involved stakeholders.
This report has several strengths and limitations. Not all
respondents completed the survey in its entirety, introducing
a potential bias in the preference to answer certain questions
related to the respondent’s background as a stakeholder. Due
to anonymity and the modest sample size, generalization
should be done with caution. Furthermore, The survey was
open for 12 months, allowing as many respondents as
possible to participate. However, the extended time frame
may also have influenced the opinions. Furthermore, it was
accessible online and the survey could be shared by non-
EUPATI.be members enabling to reach a wider audience—
no specific audience was targeted-, yet we only reached
a modest sample size. It was a nation-wide bottom-up
survey: respondents reflect the actual interest in patient
involvement. However, this is a limitation as well since
respondents interested in patient involvement may be more
likely to participate to the survey—leading to a bias in the
results, and uncertainty about actual representation of the
stakeholders in the Belgian landscape. Data was collected
anonymously, thus identities could not be verified, hampering
interpretation of the answers’ context. Furthermore, based
on the demographics we observed an underrepresentation of
several stakeholders, including policy and payer representatives.
Although the intention was to perform a nation-wide survey,
the majority of respondents were from Flanders or Brussels,
complicating interpretation for Belgium in general. Yet, by
not targeting a specific stakeholder, we provide survey-based
data from a multi-stakeholder perspective to enable mutual
understanding. This study can be viewed as a scientific
milestone in understanding the multi-stakeholder perspective
at the national level and can serve as a guidance for a pan-
European study. Lastly, based on this survey, EUPATI.be can use
evidence-based data to formulate priorities within its mission
and anticipate country-specific obstacles in order to enable
patient involvement.
CONCLUSION
Patient involvement in the lifecycle of medicines has been
recognized as one of the most promising approaches to
promote innovation in healthcare. EUPATI.be represents a
practical example of how patient involvement can be improved
through patient education, creating awareness and establishing
collaborations. EUPATI.be’s strategic work in these areas is driven
by the multi-stakeholder processes and the active involvement of
patients, industry and academia is crucial for creating a patient-
centric ecosystem—a new model helping patients to better
engage in their role. Here, we report on the Belgian perception of
patient involvement from different stakeholders’ points of view.
EUPATI.be’s mission to facilitate patient participation remains
largely unknown amongst respondents. Moreover, interpretation
of patient involvement remains mainly as study subjects in
medical research, indicative that a revision of the definition
of “patient involvement” is primordial. Based on these results,
we believe that EUPATI.be’s mission must be reinterpreted in
priority. To achieve this, we need policy makers to promote
a regulatory environment and create a sustainable framework
where patient involvement and its current barriers can be
overcome, when funding medical research.
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Ultimately, better coordination amongst various initiatives
and levels of intervention will ensure long term improvement in
patient involvement.
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